David Risinger - Morgan Stanley & Co. International

facebook_page
twitter_page

Last quote by David Risinger

We believe investors underappreciate the global prospects for Pfizer's #1 growth driver Ibrance (breast cancer). We expect Ibrance to maintain its first-to-market advantage.feedback
share this quote
Sep 20 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which David Risinger is associated, including Keytruda, Washington, and earnings. Most recently, David Risinger has been quoted saying: “We expect Merck to return to accelerating earnings growth in 2018 after six years of flat earnings driven by Keytruda growth as Merck builds on its leadership position in immuno-oncology. Our long term estimates are well above consensus.” in the article Merck to rally 15 percent on successful cancer drug, Morgan Stanley says.
Automatically powered by Storyzy
Take our quote verification challenge and find out !

Quotes by David Risinger

<
>
Quote Verifier
verify-icon
Check if the quote you read on social networks is authentic
facebook_page
twitter_page
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided
 
Feedback×

Quote :

Mistake :

Comments :